Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,161 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02684058 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | completed | Phase 2 | 151 | Novartis PharmaceuticalsINDUSTRY | 20 | Dec 13, 2023 | clinicaltrials |
| NCT03871816 | A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer | completed | — | 14,532 | Janssen Research & Development, LLCINDUSTRY | 25 | Dec 11, 2023 |
| clinicaltrials |
| NCT05444972 | A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review(METER) | completed | — | 998 | AbbVieINDUSTRY | 14 | Dec 11, 2023 | clinicaltrials |
| NCT05422820 | The Argentina Brief Colonoscopy Difficulty Score (ABCD)(ABCD) | completed | — | 5,000 | Institute of Gastroenterology and Advance EndoscopyOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05836064 | GastroBot: Artificial Intelligence Applied to Bowel Preparation | unknown | N/A | 388 | Institute of Gastroenterology and Advance EndoscopyOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05270044 | Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.(COLUMBUS-AD) | active not recruiting | Phase 3 | 815 | Pierre Fabre MedicamentINDUSTRY | 23 | Nov 22, 2023 | clinicaltrials |
| NCT04066491 | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC | terminated | Phase 2 / Phase 3 | 309 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 15 | Nov 14, 2023 | clinicaltrials |
| NCT03786094 | Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer(FORTRESS) | terminated | Phase 3 | 432 | Spexis AGINDUSTRY | 13 | Nov 1, 2023 | clinicaltrials |
| NCT02941926 | Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC(COMPLEEMENT-1) | completed | Phase 3 | 3,246 | Novartis PharmaceuticalsINDUSTRY | 38 | Oct 24, 2023 | clinicaltrials |
| NCT04246489 | Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer | completed | Phase 2 | 146 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 12 | Oct 23, 2023 | clinicaltrials |
| NCT04721002 | Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)(MEDICI) | completed | — | 514 | AbbVieINDUSTRY | 22 | Oct 18, 2023 | clinicaltrials |
| NCT03120949 | Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis(CREDO 4) | completed | Phase 3 | 2,106 | R-Pharm International, LLCINDUSTRY | 18 | Oct 12, 2023 | clinicaltrials |
| NCT02987543 | Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) | completed | Phase 3 | 387 | AstraZenecaINDUSTRY | 20 | Oct 6, 2023 | clinicaltrials |
| NCT06067594 | Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma. | completed | — | 155 | Austral University, ArgentinaOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03302234 | Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) | completed | Phase 3 | 568 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Sep 26, 2023 | clinicaltrials |
| NCT02312258 | A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT) | completed | Phase 3 | 706 | TakedaINDUSTRY | 35 | Sep 21, 2023 | clinicaltrials |
| NCT02760433 | Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease(CREDO 3) | completed | Phase 3 | 368 | R-Pharm International, LLCINDUSTRY | 11 | Sep 21, 2023 | clinicaltrials |
| NCT02998983 | Racotumomab in Patients With High-risk Neuroblastoma | completed | Phase 2 | 39 | Laboratorio Elea Phoenix S.A.INDUSTRY | 1 | Sep 11, 2023 | clinicaltrials |
| NCT04089488 | Incidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin America | completed | — | 175 | AIDS Malignancy ConsortiumNETWORK | 3 | Sep 1, 2023 | clinicaltrials |
| NCT01000025 | PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer | completed | Phase 3 | 720 | NCIC Clinical Trials GroupNETWORK | 12 | Aug 22, 2023 | clinicaltrials |
| NCT03200717 | Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment(IO-PAZ) | completed | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 21, 2023 | clinicaltrials |
| NCT03512197 | A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) | completed | Phase 3 | 511 | Novartis PharmaceuticalsINDUSTRY | 20 | Aug 21, 2023 | clinicaltrials |
| NCT03626545 | Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy(CANOPY-2) | terminated | Phase 3 | 245 | Novartis PharmaceuticalsINDUSTRY | 26 | Aug 21, 2023 | clinicaltrials |
| NCT04742192 | Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer(EARLY-EGFR) | completed | — | 601 | AstraZenecaINDUSTRY | 15 | Aug 14, 2023 | clinicaltrials |
| NCT00245154 | Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 296 | NCIC Clinical Trials GroupNETWORK | 6 | Aug 4, 2023 | clinicaltrials |
| NCT03024996 | A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy(IMmotion010) | terminated | Phase 3 | 778 | Hoffmann-La RocheINDUSTRY | 28 | Aug 3, 2023 | clinicaltrials |
| NCT03185013 | REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)(REVEAL 1) | completed | Phase 3 | 201 | Inovio PharmaceuticalsINDUSTRY | 19 | Jul 27, 2023 | clinicaltrials |
| NCT05568407 | A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer | terminated | — | 19 | PfizerINDUSTRY | 2 | Jul 13, 2023 | clinicaltrials |
| NCT05926128 | Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase(AST) | unknown | N/A | 75 | FundaleuOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT01321554 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)(SELECT) | completed | Phase 3 | 392 | Eisai Inc.INDUSTRY | 23 | Jun 22, 2023 | clinicaltrials |
| NCT01327885 | Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma | completed | Phase 3 | 452 | Eisai Inc.INDUSTRY | 23 | Jun 22, 2023 | clinicaltrials |
| NCT01347645 | Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer | terminated | Phase 1 / Phase 2 | 82 | Eisai Inc.INDUSTRY | 6 | Jun 22, 2023 | clinicaltrials |
| NCT01593254 | Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib(DASCERN) | completed | Phase 2 | 262 | Bristol-Myers SquibbINDUSTRY | 15 | Jun 22, 2023 | clinicaltrials |
| NCT02869789 | An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers | completed | Phase 4 | 1,041 | Bristol-Myers SquibbINDUSTRY | 21 | Jun 15, 2023 | clinicaltrials |
| NCT00106691 | Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia) | completed | Phase 3 | 1,589 | GTxINDUSTRY | 3 | Jun 12, 2023 | clinicaltrials |
| NCT02303444 | An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors(RIFTOS MKI) | completed | — | 667 | BayerINDUSTRY | 19 | Jun 8, 2023 | clinicaltrials |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 51 | Asana BioSciencesINDUSTRY | 2 | Jun 7, 2023 | clinicaltrials |
| NCT03519256 | A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder(CheckMate 9UT) | terminated | Phase 2 | 142 | Bristol-Myers SquibbINDUSTRY | 15 | Jun 1, 2023 | clinicaltrials |
| NCT03911869 | An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis(POLARIS) | terminated | Phase 2 | 13 | PfizerINDUSTRY | 5 | May 31, 2023 | clinicaltrials |
| NCT02573324 | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification(Intellance1) | completed | Phase 3 | 691 | AbbVieINDUSTRY | 28 | May 11, 2023 | clinicaltrials |
| NCT01698918 | Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer(BOLERO-4) | completed | Phase 2 | 202 | Novartis PharmaceuticalsINDUSTRY | 13 | May 3, 2023 | clinicaltrials |
| NCT02823574 | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(CheckMate 714) | completed | Phase 2 | 425 | Bristol-Myers SquibbINDUSTRY | 21 | May 3, 2023 | clinicaltrials |
| NCT00614211 | Laparoscopic Approach to Cervical Cancer(LACC) | completed | N/A | 636 | Queensland Centre for Gynaecological CancerOTHER_GOV | 13 | Apr 18, 2023 | clinicaltrials |
| NCT04887519 | A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC) | completed | — | 39 | TakedaINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04962880 | HRR Prevalence in LatAm PROSPECT Study(PROSPECT) | completed | — | 388 | AstraZenecaINDUSTRY | 7 | Apr 14, 2023 | clinicaltrials |
| NCT03785925 | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer(PIVOT-10) | completed | Phase 2 | 192 | Nektar TherapeuticsINDUSTRY | 18 | Mar 28, 2023 | clinicaltrials |
| NCT01881659 | Cervical Cancer Screening With Human Papillomavirus Testing(ESTAMPA) | unknown | — | 50,000 | International Agency for Research on CancerOTHER | 9 | Mar 14, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials